Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound
09 janv. 2023 01h20 HE
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR Inhaled murepavadin shown to be well tolerated at all dose levels Program derived from Spexis’ macrocycle platformData support moving forward...
Spexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas
13 déc. 2022 01h32 HE
|
Spexis AG
Balixafortide shown to have synergistic or additive effect with conventional or targeted therapies across all tested B-cell lymphomas ALLSCHWIL, Switzerland, Dec. 13, 2022 (GLOBE NEWSWIRE) --...
Spexis announces positive renal impairment clinical trial results with balixafortide
22 sept. 2022 01h20 HE
|
Spexis AG
Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and well tolerated Safety findings support potential to use significantly higher doses of balixafortide...
Spexis provides business update and announces financial results for the first half of 2022
06 sept. 2022 01h20 HE
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR Study start-up activities nearly complete for COPILOT, the first part of the Phase 3 ColiFin® program, including regulatory and ethics committee approvals...
Spexis announces presentation of half-year 2022 financial results and participation at upcoming industry and investor events in September
31 août 2022 01h30 HE
|
Spexis AG
ALLSCHWIL, Switzerland, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company...
Spexis provides business update
28 juil. 2022 01h20 HE
|
Spexis AG
Cash position to finance operations extended into January 2023Resources focused on advancing lead program, Phase 3 ColiFin®Assessment of balixafortide development options continues; balixafortide...
Spexis announces business update call to be held on July 28th
20 juil. 2022 01h30 HE
|
Spexis AG
ALLSCHWIL, Switzerland, July 20, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX) a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company...
Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model
07 juil. 2022 01h30 HE
|
Spexis AG
ALLSCHWIL, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- SPEXIS AG (SIX: SPEX), a clinical-stage biopharmaceutical company, today announced that its CXCR4 inhibitor balixafortide demonstrated...
Spexis to Present at H.C. Wainwright Global Investment Conference
19 mai 2022 01h30 HE
|
Spexis AG
ALLSCHWIL, Switzerland, May 19, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX) today announced that the company will present at the H.C. Wainwright Global Investment Conference, taking place May...
EnBiotix, Inc. Closes $11M Pre-Merger Financing
29 déc. 2021 02h30 HE
|
EnBiotix, Inc.
BOSTON, Dec. 29, 2021 (GLOBE NEWSWIRE) -- EnBiotix, Inc., a rare disease company currently focused on chronic respiratory disorders, today announced the closing of an $11M pre-merger, convertible...